affsans résumé
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial2017· article· en· The Lancet Diabetes & Endocrinology· Medicine
596
citations